نتایج جستجو برای: idarubicin
تعداد نتایج: 767 فیلتر نتایج به سال:
The optimal management of acute myeloid leukemia in patients over 60 years-of-age remains a controversial issue. The complete remission rates after conventional induction chemotherapy progressively decreases after the age of 60. This is explained by host-related factors and by differences in the biology of leukemia. The incidence of adverse prognostic factors (trilineage myelodysplasia, unfavor...
PATIENT Male, 78. FINAL DIAGNOSIS Acute myeloid leukemia (AML). SYMPTOMS Dyspnea • fatigue. MEDICATION Idarubicin followed by cytarabine. CLINICAL PROCEDURE Chemotherapy. SPECIALTY Hematology. OBJECTIVE Unusual clinical course. BACKGROUND Renal failure is a common presentation of acute myelomonocytic and monocytic leukemia. It is usually the result of a combined glomerular and tub...
We report for the first time the use of a selective small-molecule inhibitor of DNA repair to potentiate topoisomerase II (topo II) poisons, identifying DNA-dependent protein kinase (DNA-PK) as a potential target for leukemia therapy. Topo II poisons form cleavable complexes that are processed to DNA double-strand breaks (DSBs). DNA-PK mediates nonhomologous end joining (NHEJ). Inhibition of th...
The value of administering sequential courses of chemotherapy containing high-dose cytarabine in both induction and consolidation therapy for acute myeloid leukemia (AML) has not been assessed in a prospective randomized trial. Two hundred ninety-two AML patients aged 15 to 60 years were enrolled in the Australasian Leukaemia and Lymphoma Group (ALLG) AML trial number 7 (M7) protocol to evaluat...
Accidental extravasation of anthracyclines is a feared complication. Present treatment consists of local cooling and extensive surgical debridement, which often results in severe morbidity. All clinically important anthracyclines are topoisomerase II poisons that are antagonized by topoisomerase II catalytic inhibitors such as dexrazoxane. Therefore, we investigated whether dexrazoxane protects...
transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91:513-521. 6. Druker BJ, Guilhot F, O' Brien S, et al. Five-year follow-up of patients receiving ima-tinib for chronic myeloid leukemia. In t...
MDS in patients treated for APL are rare events; we report a case that shows some traits that are unusual among therapyrelated stem cell disorders. A 51-year old woman presented in May 1997 with fatigue and dyspnea. Her peripheral blood cell count showed pancytopenia with 2% abnormal promyelocytes; coagulation tests showed signs of disseminated intravascular coagulation. Bone marrow revealed 50...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید